California company raises $51 million for light-operated hearing aid

Hearing aid company Earlens has received $51 million in financing for the commercial launch of its Earlens Light Driven Hearing Aid.

Vertex Healthcare, a life science venture capital firm in Palo Alto, Calif., was the primary investor in Earlens Series C round, according to a statement from the company. Other investors included Cochlear, New Enterprise Associate, Aisling Capital, Lightstone Venture and Medtronic.

"Hearing impairment is a significant health issue globally which has been greatly underserved by conventional hearing technology," said Christopher Shen, managing director of Vertex Healthcare, in a statement. "We are pleased to be a part of the team bringing this groundbreaking new technology to market.  We believe the unique advantages of Earlens will benefit many of those hearing impaired individuals and their loved ones looking for a better solution to hearing impairment."

While most hearing aids use a small speaker to amplify sound into the ear, Earlens’ hearing aid uses focused light and a small lens to create a more natural sound while eliminating the whistling sound that occurs in many conventional hearing aids.

Now, Earlens, which is headquartered in Menlo Park, Calif., is turning its attention to raising an additional $14 million in the third quarter of this year to complete the launch of the hearing aid.

 

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup